GridAI Technologies Corp.
GRDX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$39.97M
Close$
$-0.74
112.7% downside
Current Fair Value
112.7% downsideOvervalued by 112.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $39.97 Million |
|---|---|
| Enterprise Value | $40.53 Million |
| Earnings per Share | $-4.16 |
| Beta | 1.7 |
| Outstanding Shares | 6,419,222 |
Return
| Return on Equity | -53.47% |
|---|---|
| Return on Assets | -21.48% |
| Return on Invested Capital | -97.62% |
Valuation & Multiples
| P/E Ratio | -1.3 |
|---|---|
| PEG | 1.67 |
| Price to Sales | - |
| Price to Book Ratio | 2.92 |
| Enterprise Value to Revenue | 252.8 |
| Enterprise Value to EBIT | -1.81 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$-11340.00
Consensus analyst estimateRevenue Estimate
$85,876
Consensus analyst estimateNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-11340.00
Consensus analyst estimateRevenue Estimate
$85,876
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.94%▲ 2.11% |
|---|---|
| Total Invested | $2.99M▲ 324.89% |
| Investors Holding | 19▲ 5.00% |
About First Wave BioPharma Inc
12 employees
CEO: James Sapirstein
AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. Th...